This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sharma, S.
Right arrow Articles by Khuller, G. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sharma, S.
Right arrow Articles by Khuller, G. K.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, February 2001, p. 639-640, Vol. 45, No. 2
0066-4804/01/$04.00+0   DOI: 10.1128/AAC.45.2.639-640.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.

Therapeutic Potential of Human Neutrophil Peptide 1 against Experimental Tuberculosis

Sudhir Sharma, Indu Verma, and G. K. Khuller*

Department of Biochemistry, Postgraduate Institute of Medical Education & Research, Chandigarh, India

Received 17 March 2000/Returned for modification 13 July 2000/Accepted 17 November 2000

The therapeutic efficacy of human neutrophil peptide 1 (HNP-1) against experimental tuberculosis in mice on the basis of numbers of CFU has been examined. Mice infected with 1.5 × 104 CFU of Mycobacterium tuberculosis H37Rv and treated with different doses of HNP-1 injected subcutaneously exhibited significant clearance of bacilli from lungs, livers, and spleens. There were time- and dose-dependent decreases in the bacillary load in lungs, livers, and spleens of the HNP-1-treated animals compared to that in controls (untreated animals). These observations strongly suggest the therapeutic activity of HNP-1 against tuberculosis.

* Corresponding author. Mailing address: Department of Biochemistry, Postgraduate Institute of Medical Education & Research, Chandigarh - 160 012, India. Phone: 747 585, ext. 282 or 274. Fax: 744 401. E-mail: medinst{at}pgi.chd.nic.in.

Antimicrobial Agents and Chemotherapy, February 2001, p. 639-640, Vol. 45, No. 2
0066-4804/01/$04.00+0   DOI: 10.1128/AAC.45.2.639-640.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Mendez-Samperio, P., Miranda, E., Trejo, A. (2008). Expression and Secretion of Cathelicidin LL-37 in Human Epithelial Cells after Infection by Mycobacterium bovis Bacillus Calmette-Guerin. CVI 15: 1450-1455 [Abstract] [Full Text]  
  • Rivas-Santiago, B., Hernandez-Pando, R., Carranza, C., Juarez, E., Contreras, J. L., Aguilar-Leon, D., Torres, M., Sada, E. (2008). Expression of Cathelicidin LL-37 during Mycobacterium tuberculosis Infection in Human Alveolar Macrophages, Monocytes, Neutrophils, and Epithelial Cells. Infect. Immun. 76: 935-941 [Abstract] [Full Text]  
  • Cai, S., Sato, K., Shimizu, T., Yamabe, S., Hiraki, M., Sano, C., Tomioka, H. (2006). Antimicrobial activity of picolinic acid against extracellular and intracellular Mycobacterium avium complex and its combined activity with clarithromycin, rifampicin and fluoroquinolones. J Antimicrob Chemother 57: 85-93 [Abstract] [Full Text]  
  • Domenech, P., Reed, M. B., Barry, C. E. III (2005). Contribution of the Mycobacterium tuberculosis MmpL Protein Family to Virulence and Drug Resistance. Infect. Immun. 73: 3492-3501 [Abstract] [Full Text]  
  • Fulton, S. A., Reba, S. M., Martin, T. D., Boom, W. H. (2002). Neutrophil-Mediated Mycobacteriocidal Immunity in the Lung during Mycobacterium bovis BCG Infection in C57BL/6 Mice. Infect. Immun. 70: 5322-5327 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»